Bansback, Nick
Chiu, Judy A.
Carruthers, Robert
Metcalfe, Rebecca
Lapointe, Emmanuelle
Schabas, Alice
Lenzen, Marilyn
Lynd, Larry D.
Traboulsee, Anthony http://orcid.org/0000-0002-0351-9639
Funding for this research was provided by:
VGH & UBC Hospital Foundation
Article History
Received: 10 October 2018
Accepted: 27 June 2019
First Online: 20 July 2019
Ethics approval and consent to participate
: This study was approved by the University of British Columbia Behavioural Research Ethics Board (H16–00965). All participants provided written consent prior to participating.
: Not applicable; all participants have provided consent that any feedback they provided may be used in publications without being identified.
: RC has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Teva, Novartis, EMD Serono. RC has received research support from MedImmune, Teva. EL has received personal compensation for consultancy with EMD Serono and Hoffmann-La Roche. LL has served on advisory boards from AstraZeneca, Novartis, Boehringer Ingelheim, Teva, and Pfizer. AT has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Chugai, F. Hoffmann-La Roche Ltd., Novartis, Sanofi Genzyme and Teva. AT has received research support from F. Hoffmann-La Roche Ltd.